Physician profile
Gregory Mullen
NPI 1023001245
$16,236.38
in general payments reported to CMS, 2019-2025
50 companies · $3,249 in 2025
The $3,249 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,706 · 2020: $1,640 · 2021: $1,636 · 2022: $1,727 · 2023: $2,752 · 2024: $2,527 · 2025: $3,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,527.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,965.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,349.02 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,622.72 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $1,019.72 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $1,004.67 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $747.42 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $722.24 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $569.60 | 2019-2025 | |
| Exact Sciences Corporation | $475.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $472.75 | 2019-2025 | Repatha, Repatha, Otezla |
| Astellas Pharma US INC | $371.52 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $318.81 | 2019-2024 | Xarelto |
| Abbott Laboratories | $303.39 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $261.34 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $233.01 | 2019-2022 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $213.20 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $210.71 | 2021-2025 | Gardasil 9, Capvaxive, Rotateq |
| Neurocrine Biosciences, INC. | $193.34 | 2023-2025 | Ingrezza |
| Antares Pharma, INC. | $183.34 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Verona Pharma, INC. | $163.29 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $146.20 | 2019-2025 | Rexulti |
| Boston Scientific Corporation | $144.23 | 2019 | |
| Olympus America INC. | $131.56 | 2021 | |
| Axsome Therapeutics, INC. | $127.29 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $124.58 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $123.53 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $98.11 | 2023 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $93.72 | 2023-2024 | Eliquis, Camzyos |
| Corium, LLC | $90.17 | 2023 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.87 | 2020-2024 | Relistor, Xifaxan |
| Optinose US, INC. | $65.33 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.29 | 2023-2024 | |
| Amarin Pharma, INC. | $62.67 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $57.78 | 2022 | |
| Alkermes, INC. | $57.12 | 2023 | Aristada, Lybalvi |
| Lundbeck LLC | $50.75 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $49.61 | 2020-2025 | Austedo Xr |
| Collegium Pharmaceutical, INC. | $41.33 | 2023 | Belbuca, Xtampza |
| Halozyme INC | $38.65 | 2023 | |
| Emd Serono, INC. | $37.12 | 2024 | |
| Dexcom, INC. | $21.33 | 2024 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $17.71 | 2021 | |
| Novavax INC | $17.05 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Xeris Pharmaceuticals, INC. | $16.67 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.88 | 2022 | |
| Impel Pharmaceuticals INC. | $14.78 | 2023 | Trudhesa |
| Grifols USA, LLC | $14.72 | 2020 | |
| Ibsa Pharma INC. | $14.62 | 2025 | Tirosint, Flector, Licart |
| Tolmar, INC. | $13.78 | 2025 | Jatenzo |
| Dynavax Technologies Corporation | $12.89 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Mullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.